In this issue of Blood , Chari et al 1 show that the combination of pomalidomide and dexamethasone with daratumumab induces high rates of deep and durable responses in heavily pretreated myeloma patients.
Sagar Lonial, Meletios A Dimopoulos, Jesús G. Berdeja, Paul G. Richardson, Hang Quach, Paula Rodríguez‐Otero, Paulo Maciag, Kevin Hong, Michael Amatangelo, Min Chen, Niels W.C.J. van de Donk
Paul G. Richardson, Antonio Palumbo, Stephen Schey, Meletios A Dimopoulos, Thierry Façon, Katja Weisel, Peter O’Gorman, Xavier Leleu, Martha Q. Lacy, Matthew Streetly, Joseph Mıkhael, David S. Siegel, Jesús F. San Miguel, Kenneth C. Anderson
Jonathan L. Kaufman, Meletios A Dimopoulos, Darrell White, Lotfi Benboubker, Gordon Cook, Merav Leiba, James Morton, P. Joy Ho, Kihyun Kım, Naoki Takezako, Philippe Moreau, Heather J. Sutherland, Hila Magen, Shinsuke Iida, Jin Seok Kim, H. Miles Prince, Tara Cochrane, Albert Oriol, Nizar J. Bahlis, Ajai Chari, Lisa O’Rourke, Sonali Trivedi, Tineke Casneuf,
Discussion(0)
No comments yet. Be the first to comment.